Characterization of complete responders to combination nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with advanced, unresectable melanoma.

被引：0
|
作者：
Warner, Allison Betof [1 ]
Shoushtari, Alexander Noor [1 ]
Houghton, Sean [1 ]
Panageas, Katherine [1 ]
Chapman, Paul B. [1 ]
Wolchok, Jedd D. [1 ]
Postow, Michael A. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9552
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Overall survival (OS) analysis from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL).
    Hogg, David
    Chapman, Paul B.
    Sznol, Mario
    Lao, Christopher D.
    Gonzalez, Rene
    Daniels, Gregory A.
    Smylie, Michael
    Kudchadkar, Ragini Reiney
    Thompson, John A.
    Sharfman, William Howard
    Atkins, Michael B.
    Pavlick, Anna C.
    Jiang, Joel
    Avila, Alexandre
    Demelo, Sheena
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] CHECKMATE 067: A PHASE III RANDOMIZED DOUBLE-BLIND STUDY OF NIVOLUMAB (NIVO) MONOTHERAPY OR NIVO COMBINED WITH IPILIMUMAB (IPI) VERSUS IPI MONOTHERAPY IN PREVIOUSLY UNTREATED PATIENTS (PTS) WITH ADVANCED MELANOMA (MEL)
    Wolchok, J. D.
    Chiarion-Sileni, V.
    Gonzalez, R.
    Rutkowski, P.
    Grob, J. J.
    Cowey, C. L.
    Lao, C. D.
    Schadendorf, D.
    Ferrucci, P. F.
    Smylie, M.
    Dummer, R.
    Hill, A.
    Haanen, J.
    Maio, M.
    McArthur, G.
    Yang, A.
    Rollin, L.
    Horak, C.
    Larkin, J.
    Hodi, F. S.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2015, 11 : 68 - 68
  • [23] Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204).
    Tawbi, Hussein Abdul-Hassan
    Forsyth, Peter A. J.
    Hodi, F. Stephen
    Lao, Christopher D.
    Moschos, Stergios J.
    Hamid, Omid
    Atkins, Michael B.
    Lewis, Karl D.
    Thomas, Reena Parada
    Glaspy, John A.
    Jang, Sekwon
    Algazi, Alain Patrick
    Khushalani, Nikhil I.
    Postow, Michael A.
    Pavlick, Anna C.
    Ernstoff, Marc S.
    Reardon, David A.
    Balogh, Agnes
    Rizzo, Jasmine I.
    Margolin, Kim Allyson
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [24] Phase Ib trial of selinexor (SEL) in combination with nivolumab (NIVO) alone or nivolumab plus ipilimumab (NIVO plus IPI) in patients (pts) with advanced malignancies: The renal cell carcinoma (RCC) experience.
    Alhalabi, Omar
    Tannir, Nizar M.
    Momin, Hassan Ahmed
    Yilmaz, Bulent
    Stephen, Bettzy
    Ejezie, Chinenye Lynette
    Moyers, Justin Tyler
    Gurses, Serdar A.
    How, Jeffrey
    Fu, Siqing
    Ahnert, Jordi Rodon
    Hong, David S.
    Piha-Paul, Sarina Anne
    Subbiah, Vivek
    Dumbrava, Ecaterina Elena
    Karp, Daniel D.
    Janku, Filip
    Meric-Bernstam, Funda
    Naing, Aung
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [25] Cost-effectiveness of nivolumab in combination with ipilimumab in patients with unresectable advanced melanoma in Australia
    Bohensky, M. A.
    Kim, H.
    Gorelik, A.
    Liew, D.
    ANNALS OF ONCOLOGY, 2015, 26 : 103 - 103
  • [26] CheckMate 067: a phase III randomized double-blind study of nivolumab (NIVO) monotherapy or NIVO combined with ipilimumab (IPI) versus IPI monotherapy in previously untreated patients (pts) with advanced melanoma (MEL)
    Wolchok, J. D.
    Chiarion-Sileni, V.
    Gonzalez, R.
    Rutkowski, P.
    Grob, J.
    Cowey, C. L.
    Lao, C. D.
    Schadendorf, D.
    Ferrucci, P. F.
    Smylie, M.
    Dummer, R.
    Hill, A.
    Haanen, J.
    Maio, M.
    McArthur, G.
    Yang, A.
    Rollin, L.
    Horak, C.
    Larkin, J.
    Hodi, F. S.
    ANNALS OF ONCOLOGY, 2015, 26 : 28 - 28
  • [27] FDG-PET metabolic tumor volume in advanced melanoma treated with ipilimumab and nivolumab (ipi/nivo).
    Iravani, Amir
    Wallace, Roslyn
    Lo, Serigne
    Galligan, Anna
    Weppler, Alison
    Au-Yeung, George
    Kee, Damien
    Lau, Peter Kar Han
    Brady, Benjamin M.
    Lee, Belinda
    McArthur, Grant A.
    Sandhu, Shahneen Kaur
    Hicks, Rodney J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [28] CheckMate 204: 3-year outcomes of treatment with combination nivolumab (NIVO) plus ipilimumab (IPI) for patients (pts) with active melanoma brain metastases (MBM)
    Tawbi, H. A.
    Forsyth, P. A.
    Hodi, F. S.
    Algazi, A.
    Hamid, O.
    Lao, C. D.
    Moschos, S. J.
    Atkins, M. B.
    Lewis, K.
    Postow, M. A.
    Thomas, R. P.
    Khushalani, N. I.
    Pavlick, A. C.
    Ernstoff, M. S.
    Reardon, D. A.
    Chung, C.
    Lee, W.
    Bas, T.
    Askelson, M.
    Margolin, K. A.
    ANNALS OF ONCOLOGY, 2021, 32 : S871 - S872
  • [29] Quality of life (QoL) and symptom burden in patients (pts) with advanced melanoma during the treatment-free interval (TFI) after discontinuation of nivolumab (NIVO) or NIVO plus ipilimumab (IPI).
    Taylor, Fiona
    Regan, Meredith M.
    Schadendorf, Dirk
    Atkins, Michael B.
    Lawrance, Rachael
    Moreno-Koehler, Alejandro
    Moshyk, Andriy
    Rao, Sumati
    Ritchings, Corey
    Kotapati, Srividya
    Lord-Bessen, Jennifer
    Rizzo, Jasmine I.
    McDermott, David F.
    Middleton, Mark R.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [30] Longitudinal analysis of circulating immune cell subsets in melanoma patients (pts) treated with neo-adjuvant ipilimumab (ipi) & nivolumab (nivo)
    Simpson, R. C.
    Batten, M.
    Shanahan, E. R.
    Da Silva, I. Pires
    Versluis, J. M.
    Reijers, I. L. M.
    Menzies, A. M.
    Saw, R. P. M.
    Gonzalez, M.
    Shannon, K. F.
    Spillane, A. J.
    Blank, C. U.
    Scolyer, R. A.
    Long, G. V.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1303 - S1303
12345